Forty-one previously healthy children , 2 years of age who required mechanical ventilation for respiratory syncytial virus (RSV) infection were randomized to receive dexamethasone (0.5 mg/kg; n 5 22) or saline placebo (n 5 19) intravenously every 12 h for 4 days. RSV quantity was measured by quantitative plaque assay in fresh tracheal and nasal aspirates obtained at intervals of 24 6 3 h on days 0, 1, 2, 5, and 7 following entry. Analysis by linear mixed-effects modeling demonstrated a significantly greater decline in mean tracheal RSV quantity in the placebo group than in the dexamethasone group from day 0 to day 1 (0.82 vs. 0.21 log pfu/mL; P5 .01) and from day 0 to day 2 (1.45 vs. 0.53 log pfu/mL; P5 .03). No differences were found between groups in nasal RSV quantity, white blood cell counts in tracheal or nasal aspirates, serum neutralizing antibody titers during convalescence, or duration of mechanical ventilation, intensive care unit stay, or hospital stay.
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Respiratory syncytial virus (RSV) is the leading cause of lower respiratory tract infection in infants.
Published data indicate that RSV infection results in the hospitalization of 73,400-126,300 infants annually in the United States [1] . At present, therapeutic options for the management of RSV lower respiratory tract illness are suboptimal. The pathogenesis of RSV lower respiratory infection is imperfectly understood, but pathology is likely to be mediated both by the direct effects of the virus and by the host's inflammatory response. It is unclear whether corticosteroids can ameliorate the clinical course of RSV lower respiratory disease by altering the inflammatory response. A number of clinical trials [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] have addressed the potential utility of corticosteroids in bronchiolitis, the most frequent manifestation of RSV lower respiratory infection, with conflicting results. The effects of corticosteroids on viral replication and inflammation in infants with acute RSV lower respiratory infection, however, have not been studied. The present study was designed to evaluate the effects of corticosteroid therapy on RSV quantity and white blood cell (WBC) counts in respiratory secretions, serum antibody responses, and measures of clinical outcome in infants who required mechanical ventilation for severe RSV lower respiratory infection.
Methods
Study design. A randomized, double-blind, placebo-controlled trial comparing dexamethasone to saline placebo was conducted in 2 institutions (Le Bonheur Children's Medical Center, Memphis, and Dallas Children's Hospital) over the 1997-1998 and 1998-1999 winter seasons. Randomization was performed in blocks of 4 patients at each study site. Patients were randomized in a 1:1 ratio to receive dexamethasone sodium phosphate (0.5 mg/kg/dose) or an equal volume of identically appearing normal saline intravenously every 12 h for 4 days. Each patient's attending physician, independent of the investigators, provided all other treatment.
Patients. Children were eligible for enrollment in the study if they were ,24 months of age, had RSV detected in respiratory secretions within the preceding 48 h, and were intubated and required positive-pressure mechanical ventilation for , 36 h. Exclusion criteria included blood cultures positive for known bacterial pathogens (excluding skin flora) within 72 h before enrollment; diagnosed immunodeficiency; requirement for high-frequency oscillatory venti- lation or extracorporeal membrane oxygenation before study entry; use of systemic corticosteroids within the preceding 3 weeks; use of oxygen for . 7 days for the management of chronic lung disease within the preceding 3 months; receipt of other investigational agents or ribavirin; or exposure to varicella within the preceding 21 days (unless previously infected with or immunized against varicella). During both the 1997-1998 and 1998-1999 winters, enrollment at each institution commenced after the onset of widespread RSV disease in the community and continued until the end of the RSV season.
Sample size. The study was designed for the primary outcome to be the mean difference between treatment groups in the change in RSV quantity in tracheal secretions from day 0 to day 1. Preliminary sample-size calculations were performed to ensure that the study would have adequate power to demonstrate a difference between groups of >1.0-1.5 log pfu/mL in this primary outcome, with a 2-tailed a of 0.05 and a b of 0.2. On the basis of data we had collected earlier, we assumed that the mean^SE tracheal RSV quantity on day 0 would be 4:8^0:27 log pfu/mL and that the mean change from baseline would be 20:6^0:21 log pfu/mL in the placebo group. Given these assumptions, we calculated that 11-25 subjects per group would be required. Previous experience at the participating institutions indicated that this number of subjects could be enrolled over the course of 2 winter seasons.
Clinical evaluation. All patients were examined by one of the investigators at the time of study enrollment and at least daily thereafter until the time of hospital discharge. Outcome data, including the number of ventilator, intensive care unit (ICU), and hospital days and any adverse events, were collected for all patients. For one patient, who remained in the hospital for management of complications of gastroschisis, the number of days to complete resolution of all respiratory signs and symptoms was used in place of the number of hospital days. All guardians were asked to bring their infants back for a follow-up evaluation~30 days after study enrollment.
Collection of tracheal and nasal aspirates. Tracheal and nasal aspirates were obtained from all study patients immediately before they received the first dose of study drug (day 0) and then at intervals of 24^3 h on study days 1, 2, 5, and 7. Tracheal aspirates were obtained only as long as infants continued to require endotracheal intubation; nasal aspirates were obtained as long as infants remained hospitalized.
Tracheal aspirates were obtained using the same standard method at both sites. In brief, 3 mL of nonbacteriostatic saline was instilled into the endotracheal tube, and, after 3-5 positive-pressure breaths were administered with an anesthesia bag, tracheal secretions were aspirated into a mucus specimen trap, using an 8-or 10-French suction catheter attached to low-wall suction. The secretions were immediately mixed with 3 mL of cold RSV transport medium (Eagle MEM, sucrose, penicillin, streptomycin, HEPES, L-glutamine, K 2 HPO 4 , and KH 2 PO 4 ). Nasal aspirates were also obtained using the same standard method at both sites. In brief, patients were placed in the recumbent position, and 3 mL of nonbacteriostatic saline was instilled into the nares. Nasal secretions were then immediately aspirated into a mucus specimen trap and mixed with 3 mL of cold RSV transport medium.
Quantitative RSV cultures. Quantitative RSV cultures were performed locally at each site on fresh (i.e., nonfrozen) specimens, using a standardized plaque assay. Tracheal and nasal aspirates were diluted 10-fold serially in growth medium (Eagle MEM, 10% fetal bovine serum, penicillin, streptomycin, L-glutamine, and HEPES), and 100 mL of each dilution was inoculated in triplicate on 80% confluent HEp-2 cell monolayers in 12-well clusters. After incubation at 37 C in 5% CO 2 for 1 h, inoculated monolayers were overlaid with growth medium supplemented with amphotericin B and 0.75% methylcellulose and were incubated at 37 C in 5% CO 2 for 5 days. The monolayers were then fixed with buffered formalin phosphate and were stained with hematoxylin and eosin. Plaques were counted under an inverted microscope, and the RSV quantity was calculated for each specimen, as described elsewhere [16] . To ensure reproducibility and reliability, aliquots of an RSV (Long strain) standard of known quantity were cultured in parallel with all clinical specimens at both sites.
WBC counts. WBC counts in tracheal and nasal aspirates were determined by pipetting 10 mL of fresh unspun specimen onto a hemacytometer (Neubauer) and counting WBCs under an inverted microscope. For the determination of differential counts, 10 mL of cytocentrifuged specimen was heat-fixed, and slides were stained with Wright-Giemsa stain. For each specimen, the percentage of segmented neutrophils, lymphocytes, monocytes, and eosinophils and the absolute neutrophil count per microliter (ANC) were calculated.
Serum RSV antibody titers. Serum samples were obtained from each subject on day 0 (acute serum) and at the day-30 follow-up visit (convalescent serum). All sera were kept frozen at 270 C until assayed. Serum neutralizing antibody titers to RSV/A (Long strain) were assayed, using a 60% plaque-reduction neutralization test, as described elsewhere [17] .
Statistical analysis. In all cases, statistical significance was defined as a 2-tailed a ,.05. All statistical calculations were performed using the SAS System for Windows (release 6.12; SAS Institute). Baseline data between the dexamethasone and placebo groups were compared by use of the x 2 test for categorical data and the independent t test for continuous data. The changes from baseline in RSV quantity and WBC count in tracheal and nasal aspirates were compared between groups, using the Wilcoxon rank-sum test.
The relationship of treatment group allocation to these outcome variables was further investigated using linear mixed-effects modeling. The modeling procedure used was a linear mixed-effects covariance pattern model, which has been described in detail elsewhere [18, 19] . These analyses were done to account for repeated measures, to avoid being forced into discarding cases having some missing data and to evaluate the relationships of independent variables other than treatment-group allocation to outcome variables. Separate models were developed for the dependent variables of tracheal and nasal RSV quantities and tracheal and nasal WBC counts. Infants with data available for >2 study days were included in each model. Each model evaluated the association of independent variables on the appropriate dependent variable. Independent variables included treatment group (dexamethasone vs. placebo), time (study day), chronologic age, sex, ethnicity (white vs. nonwhite), birth weight, gestational age (< 35 vs. . 35 weeks), study site (Dallas vs. Memphis), and duration of any symptom (number of days) before study entry. Interaction terms between different independent variables were investigated, but they were retained in the final model for each dependent variable only if found to be significant. For purposes of modeling, chronologic age (in days) and total WBC counts in nasal and tra-cheal aspirates (in cells per microliter) were transformed to their natural logarithms to yield normal distributions.
Ventilator, ICU, and hospital days were compared between groups, using the Wilcoxon rank-sum test. Furthermore, linear regression was used to evaluate the associations of the independent variables listed above to these measures of clinical outcome. Serum neutralizing antibody titers were compared by use of the Wilcoxon ranksum test, and the proportions of subjects with 4-fold increases in RSV antibody titer were compared by use of the x 2 test.
Results
Study population. Forty-two infants (29 in Dallas, 13 in Memphis) were enrolled and were randomized to receive dexamethasone or placebo. One enrolled infant was subsequently excluded when it was revealed that he had been receiving systemic corticosteroids for several days prior to admission. Thus, 41 infants are included in the analysis: 22 received dexamethasone and 19 received placebo. Two infants in the dexamethasone group received only the first 3 doses of study drug before intravenous access was discontinued and never reestablished. These 2 infants are included in analyses of clinical outcomes (intent to treat), but only the day 0 and day 1 tracheal aspirate and nasal aspirate samples are included in the analyses of RSV quantity and WBC count (per protocol). All other subjects completed the full 8-dose course of study drug.
Baseline characteristics of the study infants are shown in table 1. No subjects in either group had histories of reactive airway disease, RSV infection, or wheezing episodes. Bronchopulmonary dysplasia had been previously diagnosed in 2 infants in the dexamethasone group, but neither had required medical therapy for chronic lung disease within the 6 months preceding enrollment. One child in the dexamethasone group had received a single infusion of RSV immune globulin 45 days before enrollment; no other subjects had received RSV immune globulin or palivizumab before study entry.
RSV quantity in tracheal aspirates. Quantitative RSV cultures were performed on 141 tracheal aspirates. Of these, the tracheal RSV quantity could not be determined for 5 specimens from 3 patients (1 each from days 0, 1, 2, 5, and 7), because the HEp-2 cell monolayers degenerated in these plaque assays (usually as a result of bacterial or fungal overgrowth in the culture medium). Table 2 lists the mean measured RSV quantity, mean change from baseline, and number of subjects with specimens that could be analyzed for each study day. The decline from baseline in tracheal RSV quantity was significantly greater among infants in the placebo group than among those in the dexamethasone group on study days 1 and 2 (table 2 and figure 1A) . The change from baseline in measured tracheal RSV quantity did not differ significantly between groups on days 5 or 7, but the numbers of subjects who remained intubated and thus had specimens collected on these days was lower than on days 0, 1, and 2.
Linear mixed-effects modeling was used to evaluate the effects of various independent variables, including treatment group, on tracheal RSV quantity over time. Because only 9 patients remained intubated on day 7, the mixed-effects model was limited to analysis of the first 5 study days. Five patients were excluded from the model: 2 had missing baseline information regarding gestational age category or duration of symptoms before entry, and 3 had only 1 tracheal aspirate obtained before extubation. The final mixed-effects model (shown in table 3) revealed that RSV quantity in tracheal aspirate cultures varied significantly by treatment group over time (i.e., with increasing numbers of study days) in both a linear and a quadratic fashion. Furthermore, tracheal RSV quantity varied inversely with the number of days of symptoms at study entry, and infants born before 35 weeks' gestational age had higher tracheal RSV quantities than those born closer to term. As demonstrated in table 4 and figure 1B, linear mixed-effects modeling predicted that infants receiving placebo would have significantly greater declines in mean tracheal RSV quantity from baseline on days 1 and 2 than infants receiving dexamethasone. These results were consistent with those determined from direct comparisons of measured tracheal RSV quantities (table 2 and figure 1A) . The model also demonstrated that the difference in change from baseline fell just short of statistical significance on day 3 and that no difference was apparent on days 4 and 5. The modeled rate of tracheal RSV clearance (i.e., slope) was significantly greater for placebo-treated infants on days 0 and 1 but was greater for dexamethasonetreated infants on days 4 and 5 (table 4 and figure 1B) .
RSV quantity in nasal aspirates. The change from baseline in nasal RSV quantity did not differ significantly between the dexamethasone and placebo groups on any study day (data not shown). Linear mixed-effects modeling did not reveal an association between nasal RSV quantity and treatment group; however, the model did predict that nasal RSV quantity would vary inversely with time (i.e., with increasing numbers of study days; P , :0001) and with the number of days of symptoms at study entry (P ¼ :0035). Unlike tracheal RSV quantity, nasal RSV quantity also varied directly with chronologic age (P ¼ :0167), whereas gestational age was not significantly associated with nasal RSV quantity.
WBC counts in tracheal and nasal aspirates. There were no significant differences between the 2 treatment groups in change from baseline WBC count or ANC on any study day in either tracheal or nasal aspirates (data not shown). Mixed-effects modeling demonstrated that total WBC counts would significantly decrease over time in tracheal (P ¼ :02) and nasal (P ¼ :04) aspirates, but it did not identify any significant associations with treatment group or other independent variables.
Clinical outcomes. Infants in the placebo and dexamethasone groups did not significantly differ in their median (interquartile range) number of ventilator days (6.0 following study entry. Because this study was primarily designed to evaluate differences in virus quantity, our sample size is only large enough to exclude differences of > 50% between groups in ventilator or ICU days or a difference of >40% in hospital days, with 80% power (assuming that a ¼ 0:05).
Linear regression did not find treatment group to be significantly associated with ventilator, ICU, or hospital days, but significant associations with other independent variables were revealed. Chronologic age at study entry varied directly with ventilator (P ¼ :003), ICU (P ¼ :003), and hospital (P ¼ :04) days. Infants born at < 35 weeks' gestational age had increased ventilator (P ¼ :007), ICU (P ¼ :01), and hospital (P ¼ :05) days, compared with infants born closer to term. Infants hospitalized in Dallas had increased ventilator (P ¼ :03) and ICU (P ¼ :02) days, compared with infants hospitalized in Memphis (data not shown).
Serious adverse events occurred in 2 patients in the dexamethasone group. One infant developed progressive respiratory failure that did not improve with high-frequency oscillatory ventilation or extracorporeal membrane oxygenation; support was withdrawn, and this infant died on study day 38. Another subject developed a pneumothorax, which resolved following placement of a pigtail thoracostomy catheter, on study day 7. Neither Table 2 . Tracheal respiratory syncytial virus (RSV) quantities (mean and change from baseline) measured in children in a randomized, double-blind, placebo-controlled trial of dexamethasone in severe RSV infection.
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Change from baseline, mean log pfu/mL (SD) adverse event was judged to be related to administration of the study drug. No patients in either group had microscopic or gross gastrointestinal bleeding, and no patients required antihypertensive therapy during the study. Follow-up examinations were conducted~30 days after study entry for 36 infants. Of these, 3 had been treated with bronchodilators at some time between hospital discharge and the followup visit, and 3 others had received inhaled or systemic steroids. At the time of follow-up examination, mild wheezing was observed in 2 patients and mild intercostal retractions were observed in 1 patient. Seven patients had recovered from their original RSV illness but subsequently developed new symptoms of upper respiratory tract infections. There were no significant differences between treatment groups at the time of follow-up examination with regard to any of these clinical findings (data not shown).
Serum RSV antibody titers. Serum neutralizing antibody titers to RSV were assayed in paired acute and convalescent sera from 33 patients. Reciprocal antibody titers (median [range]) did not significantly differ between the placebo (n ¼ 16) and dexamethasone (n ¼ 17) groups in acute (71 vs. 63 ; P ¼ :83) or in convalescent sera (124 [34-769] vs. 113 ; P ¼ :51). The proportion of patients with a 4-fold increase in reciprocal antibody titer from acute to convalescent sera was similar in the placebo (7/16) and dexamethasone (5/ 17) groups (P ¼ :39).
Discussion
The present study differs from previous studies of corticosteroid therapy for RSV lower respiratory tract infection in infants in 2 important ways. First, we measured the effects of steroid therapy on RSV quantity and WBC counts in respiratory secretions from RSV-infected infants. Second, we restricted our study population to infants with severe RSV lower respiratory tract infection requiring mechanical ventilation. We chose to study intubated infants with severe RSV disease because of the uncertain clinical efficacy of steroid therapy in this population and because the presence of the endotracheal tube allows for serial sampling of the lower respiratory tract.
We found that 0.5 mg/kg dexamethasone administered every 12 h for 4 days to recently intubated infants with severe RSV disease significantly impaired the natural decline in tracheal RSV quantity, compared with that observed in placebo-treated infants. This effect was most pronounced at 24 and 48 h after the initiation of dexamethasone therapy and was not statistically significant on subsequent study days. Indeed, by day 5 (24 h after the final dose of dexamethasone), tracheal RSV quantities in the 2 groups were virtually identical. The impaired decline in tracheal RSV quantity is interesting in light of previous work [20] [21] [22] that suggested a positive correlation between nasal RSV quantity and disease severity in hospitalized infants. It should be emphasized that the clinical significance of an impaired decline in lower respiratory tract RSV load at this time in the disease course is unknown. Nonetheless, our findings raise questions regarding the immune mechanisms responsible for restricting early RSV replication in the lower respiratory tract. The finding that RSV quantity can be affected so soon after initiation of dexamethasone treatment suggests a steroid effect on innate immune responses rather than an inhibition of antibody-mediated viral neutralization or of T cell-mediated viral clearance.
We found that dexamethasone therapy did not affect RSV load in the upper respiratory tract, in contrast to its effects in lower respiratory secretions. This difference may be due to differing pharmacokinetics of dexamethasone in these locations. In any Table 4 . Mean difference in the quantity of tracheal respiratory syncytial virus (RSV) predicted for dexamethasone and placebo groups by linear mixed-effects modeling in a randomized, double-blind, placebocontrolled trial of dexamethasone in severe RSV infection.
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Difference in tracheal RSV quantity, log pfu/mL Differential change from day 0, log pfu/mL event, this finding underscores the importance of sampling the secretions of the lower respiratory tract in studies of RSV pathogenesis and, especially, in studies involving therapeutic interventions. One mechanism by which steroids might ameliorate the course of RSV lower respiratory infection is by decreasing airway inflammation. In this light, it is interesting to note that dexamethasone therapy did not affect total WBC counts in either upper or lower airway secretions in this study. This lack of effect may simply indicate that total WBC count is not an adequately sensitive marker of respiratory inflammation to be clinically meaningful. Concentrations of cytokines and chemokines in respiratory secretions might be more useful as markers of respiratory inflammation, and the association of some of these inflammatory mediators with RSV disease severity has been investigated [23] [24] [25] . Further analyses of the nasal and tracheal aspirates are planned, to characterize differences in cytokine and chemokine profiles between the study groups.
The clinical utility of corticosteroids in the management of RSV lower respiratory infection in infants has been debated and studied in clinical trials since the early 1960s. Comparisons of these trials are difficult, because studies have used different inclusion and exclusion criteria, steroid preparations, doses, routes of administration, and clinical outcome measures. In most of these trials, enrollment was not limited to infants with confirmed RSV infection. Two such studies [2, 7] reported that dexamethasone therapy benefited infants with bronchiolitis; however, these reports were limited by unclear inclusion and exclusion criteria [2] and by inclusion of children with both first-time and recurrent wheezing [7] . Other studies have not found measurable clinical benefits of systemic [3-6, 8, 9, 11] or nebulized [14, 15] steroids in infants with bronchiolitis. The efficacy of steroid therapy in infants with confirmed RSV infection has been evaluated in 3 randomized, controlled trials: van Woensel et al. [12] found greater improvements in clinical score among steroid recipients; Bulow et al. [13] found no differences in clinical status 1 month or 1 year after hospital discharge; and DeBoeck et al. [10] found no differences in evolution of respiratory rate, oxygen saturation, clinical score, or pulmonary function tests on day 3. The duration of hospitalization did not differ significantly between steroid and placebo groups in any of these 3 trials. Although a meta-analysis [26] of 6 randomized trials found a significant reduction in the mean duration of hospitalization among steroid-treated infants, the magnitude of this reduction was only 0.43 days (95% confidence interval [CI], 0.05-0.81 days).
We did not find any significant differences between the dexamethasone and placebo groups with regard to ventilator, ICU, or hospital days. These findings are important, because data on the clinical efficacy of steroid therapy in ventilated infants with severe RSV infection are limited. van Woensel et al. [12] reported that, among 14 infants requiring mechanical ventilation for RSV infection, those treated with prednisolone (1 mg/kg/day orally for 7 days) had shorter hospital stays than did those receiving placebo (mean difference, 7.0 days; 95% CI, 1.8-10.2 days; P , .01), but the reduction in ventilator days in the prednisolone group was not significant (mean difference, 1.6 days; 95% CI, 2 5.8 to 2.7 days; P ¼ :56). In our larger study of 41 intubated patients, we did not find that dexamethasone therapy resulted in any such reduction in hospital stay. Although our sample size is only large enough to exclude 40%-50% differences between the groups in these clinical end points with 80% power, our results add to a growing body of published evidence arguing against a clinical benefit of steroid therapy in respiratory illnesses caused by RSV. It may still be that therapy designed to modulate the immune response to RSV infection might be of benefit if given to the right subset of patients at the proper time in the disease course and perhaps in combination with specific antiviral therapy. The choice of steroid agent may also be important: In RSVinfected cotton rats, combined therapy with palivizumab and dexamethasone is less effective than combined therapy with palivizumab and either triamcinolone or methylprednisolone in reducing histologic evidence of pulmonary inflammation [27] . Despite these considerations, the weight of evidence accumulated to date does not support the routine use of steroids in the clinical management of infants with RSV lower respiratory disease.
Our results should be interpreted in the context of potential limitations of the study. Slight variations in specimen volume or quality could affect measured quantities of virus, but we minimized these variations by standardizing the volume of saline instilled into endotracheal tubes and nares and the volume of RSV transport medium mixed with each specimen. To further ensure the reproducibility of our assay, we quantitatively cultured a stock RSV sample of known quantity in parallel with each clinical specimen. Because RSV quantity is expressed as a logarithmic value, the effects of possible minor variations in technique are minimized. It is highly unlikely that minor variations in specimen volume or quality would result in the significant differences between the randomized groups found in this study. Another potential limitation of our study design is that, because many subjects improved and were extubated and/or discharged from the hospital before day 7, the analyses of RSV quantity and WBC counts are potentially influenced by missing data points. This limitation particularly applies to the analyses of tracheal aspirates, in that we could not obtain these specimens after subjects stopped requiring mechanical ventilation. Missing data also resulted from cellular degeneration in the quantitative RSV cultures, but this problem affected only 5 of 141 tracheal specimens. To minimize the effects of missing data, we analyzed the relationships of treatment group to RSV quantity and WBC count, using linear mixed-effects modeling. Because the significant differences in measured tracheal RSV quantity between groups (table 2 and figure 1A ) remain significant in the modeled analysis (table 4 and figure lB ), we are confident that these differences result from treatment effect and not from effects of missing data.
We conclude that the administration of dexamethasone to recently intubated infants with severe RSV disease significantly impairs the decline in RSV quantity in the lower respiratory tract. This effect is noted within the first 24 and 48 h after the initiation of therapy. Further study is needed to determine the lower respiratory immune mechanisms affected by dexamethasone and to clarify the clinical significance of impaired clearance of RSV from the lower respiratory tract.
